BOSTON, Sept. 6 /PRNewswire-FirstCall/ -- PAREXEL Consulting, a leading global life sciences consultancy and division of PAREXEL International Corporation (Nasdaq: PRXL - News), today announced that it has expanded its risk management and strategic compliance expertise with the appointment of Anthony C. Warchut, formerly an investigator in the U.S. Food and Drug Administration (FDA) Pharmaceutical Inspectorate. Mr. Warchut brings 29 years of FDA pharmaceutical inspection experience to PAREXEL Consulting, and joins a global network of consultants dedicated to addressing the full range of risk management challenges facing companies.
